How do roscovitine and tamoxifen's different mechanisms both effectively reduce Cdk5 levels in AD?

The abstract states these drugs have different mechanisms of action but both target Cdk5, yet provides no mechanistic explanation. Understanding these distinct pathways is crucial for optimizing combination therapy and predicting efficacy.

Gap type: unexplained_observation Source paper: Potential cure of Alzheimer’s disease by reducing the level of Cdk5 using two drugs, each with a different modus operandi. (2025, Journal of Alzheimer’s disease reports, PMID:40290779)

Resolution requires: (1) head-to-head biochemical comparison of roscovitine vs tamoxifen in neuronal cell models measuring Cdk5 activity (pThr186 western blot) and downstream substrate phosphorylation with EC50 values for each drug; (2) transcriptomic profiling (RNA-seq) showing distinct pathway activation patterns for each drug’s Cdk5-lowering mechanism; (3) combination therapy experiments in primary neurons or iPSC-derived neurons demonstrating additive or synergistic neuroprotective effects at sub-EC50 doses of each drug. Correlation of Cdk5 reduction with efficacy without mechanistic distinction is insufficient.